ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
US:NASDAQ Investor Relations: arcabio.com/investors
FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)PRECISION-AF clinical trial initiation anticipated in the first quarter of 2020 WESTMINSTER, Colo., Aug. 01, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2019 and provided a corporate update. Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. “We continue to make important progress on our lead development program Gencaro building on our GENETIC-AF Phase 2B clinical
[Read more]
| Impact snapshot | Event time: | ABIO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ABIO alerts
ABIO alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABIO alerts
High impacting ARCA Biopharma, Inc news events
Weekly update
A roundup of the hottest topics
ABIO
News
- ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19GlobeNewswire
- ARCA biopharma Announces Location Change for 2020 Annual Meeting of StockholdersGlobeNewswire
- ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment [MarketWatch]MarketWatch
- AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track DesignationGlobeNewswire
- ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
- More
ABIO
SEC Filings
- 1/13/21 - Form 4
- 1/13/21 - Form 4
- 1/13/21 - Form 4
- ABIO's page on the SEC website
- More